Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15101 - 15125 of 15701 in total
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression …
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
Matched Description: … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone …
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … is developing as a treatment for allergic reactions of the skin, such as those associated with hives and
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … orally administered drug candidate under development by Merck for the treatment of atherosclerosis and
Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Investigational
Matched Description: … [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis …
Pentanal is a solid. This compound belongs to the polyamines. These are compounds containing more than one amine group. This drug targets the protein cAMP-dependent protein kinase catalytic subunit alpha.
Experimental
Experimental
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Iupac: … N-[(1S)-1-(3-fluorophenyl)-3-[(1R,3S,5S)-3-[2-methyl-5-(2-methylpropanoyl)-1H,4H,5H,6H,7H-imidazo[4,5 …
Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Investigational
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
Experimental
Exicorilant is under investigation in clinical trial NCT03437941 (Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With Mcrpc).
Investigational
Matched Iupac: … 2-[(4aR,8aS)-1-(4-fluorophenyl)-6-[(2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H,8aH …
Experimental
Matched Iupac: … amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl
Investigational
Matched Iupac: … hydroxymethyl)oxolan-2-yl]oxy}-6-({[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl
Displaying drugs 15101 - 15125 of 15701 in total